SCHEMBL3756367

SCHEMBL3756367

Cc1cc(CNC(=O)C2c3ccccc3C(=O)N2C(CF)Cc2ccccc2)no1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.51
SCN9A Q15858 3/20 0.43
KCNH2 Q12809 2/20 0.43
SCN5A Q14524 2/20 0.43
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
FPR1 P21462 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
P2RX7 Q99572 1/20 0.38
CYP2D6 P10635 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3942929 0.83 TDP1 (0.45) KCNA5SCN9AKCNH2SCN5ATDP1
SCHEMBL3749074 0.80 KCNA5 (0.60) KCNA5SCN9AKCNH2SCN5AP2RX7
SCHEMBL3758283 0.79 KCNA5 (0.59) KCNA5SCN9AKCNH2SCN5ATDP1
SCHEMBL3753809 0.78 KCNA5 (0.53) KCNA5SCN9AKCNH2SCN5ALMNA
SCHEMBL3750868 0.77 KCNA5 (0.56) KCNA5SCN9AKCNH2SCN5ATDP1
SCHEMBL3756691 0.72 KCNA5 (0.66) KCNA5SCN9AKCNH2SCN5ATDP1
SCHEMBL13568314 0.69 SCN9A (0.69) KCNA5SCN9AKCNH2SCN5A
SCHEMBL4347580 0.69 EPHX2 (0.43) MAPK1CYP1A2CYP2C19MAPTRECQL
SCHEMBL3755943 0.68 KCNA5 (1.00) KCNA5SCN9AKCNH2SCN5ATDP1
SCHEMBL3750217 0.67 KCNA5 (0.76) KCNA5SCN9AKCNH2SCN5ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 KCNA5 69/4885SCN9A 119/4885KCNH2 2/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 KCNA5 72/4885SCN9A 177/4885KCNH2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.